Uncategorized
CB21 Pharma Successfully Passes Certification Audit for Dronabinol Manufacturing
CB21 Pharma, a leading pharmaceutical company focused on developing and marketing innovative cannabinoid-based treatments, is pleased to announce the successful completion of its certification audit for manufacturing plant-derived Dronabinol by the State Institute for Drug Control (SÚKL).
